DV
Dividend Vision

GERN — Geron Corporation

Geron Corporation (GERN)

Total return is -79.9% over the past 30 years, 2011.1 points behind SPY at 1931.2%. Its deepest 1-year drawdown was 43.6%.

Geron is an individual equity stock rather than a diversified ETF, representing a single biotechnology company focused on telomerase-based cancer therapeutics and regenerative medicine. As a single-stock holding with no dividend distribution history, it does not offer a yield profile typical of income-focused investments. This security appeals primarily to growth-oriented investors seeking exposure to early-stage biotech innovation rather than current income generation.

GERN key facts

Asset type
Stock
Asset class
Equity
Inception date
07/31/1996
Distribution frequency
None
Last close
$1.47
Market cap
$943,035,840
Average volume
11154600.0
Beta
0.588
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.11